BetterLife Pharma (BETRF) Non-Current Assets (2011 - 2026)
BetterLife Pharma (BETRF) posted quarterly Non-Current Assets of $143280.2 for Q1 2026, up 6.6% year-over-year from $134408.9 in Q1 2025, and up 6.6% quarter-over-quarter from $134408.9 in Q1 2025.
BetterLife Pharma (BETRF) Non-Current Assets (2011 - 2026) Analysis & Trends
BetterLife Pharma's Non-Current Assets history runs 16 years deep, the most recent figure standing at $143280.2 for Q1 2026.
- In Q1 2026, Non-Current Assets rose 6.6% year-over-year to $143280.2; the TTM figure through Jan 2026 stood at $474193.7 (up 41.81% YoY), while the FY2026 annual figure was $143280.2, up 6.6% from the prior year.
- Non-Current Assets for Q1 2026 stood at $143280.2, up from $134408.9 in the prior quarter.
- The five-year high for Non-Current Assets was $197230.5 in Q1 2024, with the low at -$725.83 in Q1 2023.
- The 5-year median for Non-Current Assets is $12740.8 (2022), against an average of $63788.9.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets plunged 104.98% in 2023, then surged 27273.27% in 2024.
- BetterLife Pharma's Non-Current Assets stood at $3469.3 in 2022, then sank by 120.92% to -$725.83 in 2023, then soared by 27273.27% to $197230.5 in 2024, then sank by 31.85% to $134408.9 in 2025, then gained by 6.6% to $143280.2 in 2026.
- Business Quant data shows BETRF's Non-Current Assets at $143280.2 in Q1 2026, $134408.9 in Q1 2025, and $197230.5 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 18.06 Bn |
| 10 | BetterLife Pharma | 33.62 Mn | 33.60 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | 143,280.24 |
| Jan 31, 2025 | 134,408.87 |
| Jan 31, 2024 | 197,230.46 |
| Jan 31, 2023 | -725.83 |
| Oct 31, 2022 | 3,469.34 |
| Jul 31, 2022 | 7,166.47 |
| Apr 30, 2022 | 10,916.39 |
| Jan 31, 2022 | 14,565.15 |
| Oct 31, 2021 | 18,330.07 |
| Jul 31, 2021 | 22,509.07 |
| Apr 30, 2021 | 25,625.63 |
| Jan 31, 2021 | 28,659.87 |
| Oct 31, 2020 | 8.80 Mn |
| Jul 31, 2020 | 3.38 Mn |
| Apr 30, 2020 | 3.45 Mn |
| Jan 31, 2020 | 3.63 Mn |
| Oct 31, 2019 | 6.38 Mn |
| Jul 31, 2019 | 6.61 Mn |
| Apr 30, 2019 | 7.03 Mn |
| Jan 31, 2019 | 7.58 Mn |